Please login to the form below
5
Revenue 2017Merck & Co.
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Merck & Co.'s 2013 sales performance.
HTA guidance from NICE, the SMC and the AWMSG
NICE has said that the recently-approved combination of Merck &Co/MSD’s Keytruda with Pfizer’s Inlyta shouldn’t be. ... To discuss how we can support your guidance or implementation needs please contact marketing@mgp.co.uk.
NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer
Picks up approval as a first-line treatment for advanced cancer. The UK’s National Institute for Health and Care Excellence (NICE) has recommended Merck KGaA and Pfizer’s immunotherapy Bavencio ... number of cancer immunotherapies including Merck
Roche’s Tecentriq combo scores FDA approval for melanoma
However, Roche is likely to face fierce competition from rival checkpoint inhibitors, namely Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo which have already been on the market
Sarah Matthew named as new Hanover Health Chair
Sarah Matthew co-founded Virgo Health in 2003, which grew into one of the leading international healthcare communication agencies.
AZ strengthens Daiichi Sankyo partnership with new ADC deal
The NSCLC market is particularly lucrative, and is currently dominated by Merck &Co’s Keytruda (pembrolizumab), a PD-1 inhibitor which has become a standard treatment for newly-diagnosed NSCLC patients
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
- New data backs remdesivir for COVID-19, but rings hydroxychloroquine alarm bell
- A new era for patient services?
- UK government and GSK/Sanofi sign COVID-19 vaccine supply deal
- COVID-19 round-up: WHO pulls hydroxychloroquine study, UK restricts dexamethasone exports, and more
- The blurred lines between sepsis and COVID-19
- BMS/bluebird bio resubmit FDA application for myeloma CAR-T
- Live Webinar: Using Health IT to Improve the Healthcare System
- J&J’s COVID-19 vaccine generates positive pre-clinical results
- Gilead’s top-line slips 10% as demand for HIV/hepatitis C drugs drops
- NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer
- Roche’s Tecentriq combo scores FDA approval for melanoma
- Covid-19 drives change in long-term conditions management
PMHub
Envision Pharma Group
We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...
Latest intelligence
- Covid-19 drives change in long-term conditions management
- Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore how patients are being empowered to manage their conditions at home...
- The importance of health literacy in patient recruitment materials
- Have you ever read something that instantly made you want to read on? Or have you begun to read something, and eventually given up because it didn’t resonate with you?...
- Secondary effects of COVID-19 on the healthcare system and patients
- We are getting to the point where we need to start considering the long-term effects on the healthcare system when making decisions....
Quick links
Infographics
